J&J completes $6.5B acquisition of Momenta

By The Science Advisory Board staff writers

October 1, 2020 -- Johnson & Johnson has successfully completed its acquisition of Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion.

The acquisition was completed on October 1. Shares of Momenta were purchased by Johnson & Johnson's tender offer for $52.50 per share. As a result, Momenta's common stock will be delisted from the Nasdaq Global Select Market.

The acquisition will strengthen Johnson & Johnson's presence in the rare disease medicines space.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.